Gene Therapies For Eternal Youth
By Stav Dimitropoulos,
proto.life
| 08. 03. 2023
Imagine a not-so-distant future, when a 60-year-old man named John Doe goes to the doctor to replace a faulty gene or insert a whole new gene into his body—something that cures his diabetes, for instance. This is no pipe dream.
So far, gene therapy has been approved by the U.S. Food and Drug Administration (FDA) for only a couple of applications like rare inherited diseases and blood cancer. That said, more than 2,000 clinical trials are taking place in 2023, with 200 of them having already reached phase 3 clinical trials. A slew of upcoming gene therapies could be approved—possibly in the months to come—in the United States and Europe, targeting everything from sickle cell disease and hemophilia to metastatic skin cancer. In this future, gene therapy will be approved for everything we can imagine—and many things we can’t.
Now fast forward 10 more years. That same man and his peers will have counted 70 circles round the sun. But John will remain biologically 60. At the same time, someone who is 30 years old in the year 2033 could...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...